TREATMENT OF URINARY INFECTIONS WITH TETROXOPRIM-SULFADIAZINE

A clinical trial was done on the properties of a new chemotherapeutic agent, a combination of tetroxoprim (100 mg) plus sulphadiazine (250 mg), as treatment of acute and chronic urinary tract infection. The preparation was compared with a marketed product, co-trimoxazole. The observation period was 6 weeks, including a treatment period of 10 to 14 days. The impression gained from this study, especially when considering urine status, was this new chemotherapeutic agent showed an improved effectiveness over the control treatment. No increase in resistance of organisms to tetroxoprim/sulphadiazine or co-trimoxazole was observed. © 1979 Oxford University Press.